YZ129 (YZ-129) is a small molecule inhibitor of HSP90-Calcineurin-NFAT pathway, suppresses TG-induced NFAT nuclear translocation in HeLa cellswith IC50 of 820 nM.

YW3-56 is a potent peptidylarginine deiminase (PAD) inhibitor with inhibitory activity against PAD2 (IC50=0.5-1 uM) and PAD4 (IC50=1-2 uM), inhibits U2OS cancer cell growth with IC50 of 2.5 uM.

YU142670 is a highly specific, soluble OCRL/INPP5B inhibitor that directly interacts with the catalytic domain of INPP5B.

YPC-22026, a metabolically stable derivative of YPC-21661, is a novel small molecule inhibitor of the transcription factor Zinc-finger protein 143 (ZNF143), inhibits the binding of ZNF143 to DNA.

YPC-21661 is a novel small molecule inhibitor of the transcription factor Zinc-finger protein 143 (ZNF143).

Yohimbine is an indole alkaloid that has high affinity for the α2-adrenergic receptors with Ki of 1 nM for α2A, α2B and α2C.

YM116 is a potent CYP17A1 (17,20-lyase) inhibitor with IC50 with Ki of 0.38 nM, inhibits C17-20 lyase activity in human testicular microsomes with IC50 of 4.2 nM.

YM 254890 is a selective Gq signaling inhibitor that strongly inhibits intracellular calcium ion mobilization and serum response element (SRE)-mediated transcription stimulated by several receptors coupled to Gq, but not those coupled to Gi, Gs, or G15.

YLC2-155 is a novel potent HIV-1 reverse transcriptase (RT) inhibitor that inhibits both polymerase (IC50=2.6 uM) and RNase H function (IC50=0.65 uM) of RT.

YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

YKL-1-116 is a potent, selective and covalent inhibitor of CDK7 that does not inhibit other CDKs.

YK5 is a small molecule inhibitor of Hsp70 and Hsc70, induces the degradation of HER2, Raf-1, and Akt kinases, also induces apoptosis in the SKBr3 breast cancer cells..

YIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM).

YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).

YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).

YIL-781 Ghrelin receptor antagonist (GHS-R1a) (Ki = 17 nM).

YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

YH12852 is a potent, highly selective 5-HT4 receptor agonist with pKi of 10.3, exhibits more potent agonistic activity (pEC50=11.4) than both tegaserod and prucalopride.

Y-39983 (Y39983) is a potent and selective p160 ROCK inhibitor with Ki of 140 nM.

Y08060 is a potent and selective BET inhibitor with Kd of 306 nM for BRD4 BD1, displays excellent selectivity for BET subfamily over other non-BET family with the exception of moderate inhibition of CBP/EP300.

XZH-5 is a small moelcule that inhibits constitutive and interleukin-6-induced STAT3 phosphorylation, inhibits STAT3 DNA binding ability and downregulation of STAT3 downstream genes.

Xylometazoline HCl

Xylazine Hydrochloride is α2 class of adrenergic receptor agonist.

XX-650-23 is a small molecule inhibitor of CREB, blocks CREB/CBP interaction (IC50=3.2 uM) and disrupts CREB-driven gene expression.

XR-5000 (Acridine Carboxamide.

XR 5118 is a small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 3.5 uM, binds to PAI-1 and reduces plasma PAI-1 activity levels, promotes endogenous thrombolysis and inhibits thrombus accretion.

XMU-MP-2 is a potent and selective BRK/PTK6 (breast tumor kinase) inhibitor with biochemical IC50 of 3.2 nM.

XL647 is a novel spectrum-selective kinase inhibitor for EGFR, ErbB2, KDR, Flt-4 and EphB4 with IC50 of 0.3 nM, 16 nM, 1.5 nM, 8.7 nM and 1.4 nM, respectively.

XL-281 (BMS 908662) is a potent, selective, orally active inhibitor of wild-type and mutant RAF kinases with anti-tumor activity in multiple xenograft models.